Robert W. Robey

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

The paper identifies SLC43A1 (LAT3) as a key determinant of oxaliplatin sensitivity in colorectal cancer cells through CRISPR screens and functional validation.

This study reveals the conformational dynamics of zebrafish Abcb4 using cryo-EM, showing its open-and-close motion and substrate-binding flexibility, which may explain its polyspecificity.

This paper shows that combining HDAC and eIF4A inhibitors effectively treats pancreatic cancer by inducing epigenetic reprogramming and metabolic stress in preclinical models.

The paper investigates how Angubindin-1 disrupts the blood-tumor barrier by targeting Angulin-1/LSR, enhancing drug permeability and reducing glioma progression.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This study identifies ADC payloads transported by ABC transporters, showing potential for drug resistance and suggesting payload selection to avoid this.

The paper identifies NanoLuciferase substrates transported by human and zebrafish ABC transporters at the BBB, aiding in the development of a transgenic zebrafish model to detect BBB disruptors.

This study shows that TMT1A's ability to methylate thiol-based HDAC inhibitors is conserved across species, suggesting its functional relevance in animal models.

The paper compares cancer cell growth and gene expression in different oxygen environments, finding that controlled oxygen delivery in 3D cultures better mimics physiological conditions.